cis-[Ru(NO)Cl(pyca)
2] (pyca = 2-pyridinecarboxylato), in which the two pyridyl nitrogen atoms of the two pycaligands coordinate at the trans position to each other and the two carboxylic oxygen atoms at the trans position tothe nitrosyl ligand and the chloro ligand, respectively (type
I shown as in Chart 1), reacted with NaOCH
3 to generate
cis-[Ru(NO)(OCH
3)(pyca)
2] (type
I). The geometry of this complex was confirmed to be the same as the startingcomplex by X-ray crystallography: C
13.5H
13N
3O
6.5Ru; monoclinic,
P2
1/
n;
a = 8.120(1),
b = 16.650(1),
c = 11.510(1) Å;
= 99.07(1)
;
V = 1536.7(2) Å
3;
Z = 4. The cis-trans geometrical change reaction occurred in thereactions of
cis-[Ru(NO)(OCH
3)(pyca)
2] (type
I) in water and alcohol (ROH, R = CH
3, C
2H
5) to form [{
trans-Ru(NO)(pyca)
2}
2(H
3O
2)]
+ (type
V) and
trans-[Ru(NO)(OR)(pyca)
2] (type
V). The reactions of the trans-form complexes,
trans-[Ru(NO)(H
2O)(pyca)
2]
+ (type
V) and
trans-[Ru(NO)(OCH
3)(pyca)
2] (type
V), with Cl
- in hydrochloric acid solutionafforded the cis-form complex,
cis-[Ru(NO)Cl(pyca)
2] (type
I). The favorable geometry of [Ru(NO)X(pyca)
2]
n+ dependedon the nature of the coexisting ligand X. This conclusion was confirmed by theoretical, synthetic, and structuralstudies. The mono-pyca-containing nitrosylruthenium complex (C
2H
5)
4N[Ru(NO)Cl
3(pyca)] was synthesized by thereaction of [Ru(NO)Cl
5]
2- with Hpyca and characterized by X-ray structural analysis: C
14H
24N
3O
3Cl
3Ru; triclinic,
P,
a = 7.631(1),
b = 9.669(1),
c = 13.627(1) Å;
= 83.05(2),
= 82.23(1),
= 81.94(1)
;
V = 981.1(1) Å
3;
Z = 2. The type
II complex of
cis-[Ru(NO)Cl(pyca)
2] was synthesized by the reaction of [Ru(NO)Cl
3(pyca)]
- or[Ru(NO)Cl
5]
2- with Hpyca and isolated by column chromatography. The structure was determined by X-ray structuralanalysis: C
12H
8N
3O
5ClRu; monoclinic,
P2
1/
n;
a = 10.010(1),
b = 13.280(1),
c = 11.335(1) Å;
= 113.45(1)
;
V= 1382.4(2) Å
3;
Z = 4.